Meeting
2016 Gastrointestinal Cancers Symposium
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
Authors
Vincent J. Picozzi
Virginia Mason Medical Center, Seattle, WA
Vincent J. Picozzi , Flavio G. Rocha , Scott Helton , Kabir Mody , Horacio Asbun , Michael J. Pishvaian , Patrick G Jackson , Tina Etheridge , Mairead Carney , Thomas B Neff , Seth Porter , Gerald Crans , Frank Valone , Wen Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02210559
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 457)
DOI
10.1200/jco.2016.34.4_suppl.457
Abstract #
457
Poster Bd #
N7
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
First Author: Vincent J. Picozzi
Poster
2015 Gastrointestinal Cancers Symposium
A randomized, open-label, phase I/II trial of gemcitabine plus nab-paclitaxel with or without FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer.
First Author: Flavio G. Rocha
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez
Poster
2024 ASCO Gastrointestinal Cancers Symposium
KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.
First Author: Amit Jethanandani